HSK55718 Phase 2 Trial, 200 Subjects, Orthopedic Surgery
ClinicalTrials.gov Studies
Summary
ClinicalTrials.gov has registered a multi-center, randomized, double-blind, placebo/active-controlled Phase 2 study (NCT07551739) evaluating HSK55718 for postoperative pain treatment in 200 subjects undergoing orthopedic surgery under general anesthesia. Subjects will be randomized into the HSK55718 group, morphine group, and placebo group, with HSK55718 tested at three dose levels. The trial is registered with planned start date of April 27, 2026.
“This is a multi-center, randomized, double-blind, placebo/active-controlled study. 200 subjects undergoing orthopedic surgery under general anesthesia are planned to be enrolled and randomized into the HSK55718 group, morphine group, and placebo group.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
NIH registered a new Phase 2 clinical trial (NCT07551739) on ClinicalTrials.gov for HSK55718, an investigational analgesic for postoperative pain in orthopedic surgery. The multi-center, randomized, double-blind, placebo/active-controlled study plans to enroll 200 subjects randomized into five arms: three HSK55718 dose levels, morphine active control, and placebo. The trial is sponsored under the NCT07551739 identifier. Sponsors, clinical investigators, and institutional review boards involved in drug development programs for postoperative analgesia should be aware of this competitive asset entering Phase 2 evaluation.
Archived snapshot
Apr 27, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
A Clinical Trial Evaluating the Efficacy and Safety of HSK55718 in Patients for Postoperative Pain Treatment in Orthopedic Surgery
Phase 2 NCT07551739 Kind: PHASE2 Apr 27, 2026
Abstract
This is a multi-center, randomized, double-blind, placebo/active-controlled study. 200 subjects undergoing orthopedic surgery under general anesthesia are planned to be enrolled and randomized into the HSK55718 group, morphine group, and placebo group.
Conditions: Pain After Surgery
Interventions: HSK55718 dose level 1, HSK55718 dose level 2, HSK55718 dose level 3, placebo, morphine
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.